Literature DB >> 16228299

G-protein-coupled receptor agonists differentially regulate basal or tumor necrosis factor-alpha-stimulated activation of interleukin-6 and RANTES in human airway smooth muscle cells.

Chien-Da Huang1, Alaina J Ammit, Omar Tliba, Han-Pin Kuo, Raymond B Penn, Reynold A Panettieri, Yassine Amrani.   

Abstract

Using thapsigargin (Tg), an agent that mobilizes calcium by directly emptying intracellular stores, we previously showed that intracellular calcium may play an important role in the regulation of intercellular adhesion molecule (ICAM)-1 gene expression induced by cytokines in human airway smooth muscle (ASM) cells. In the present study, we extended this previous observation by comparing the effect of Tg and other calcium-mobilizing G-protein-coupled receptor (GPCR) agonists on the expression of different pro-inflammatory genes in response to tumor necrosis factor (TNF)-alpha in ASM cells. We found that in resting cells, Tg (10-100 nM) or the bradykinin (BK) (1-10 muM) and thrombin (Thr) (1 U/ml) stimulated interleukin (IL)-6 secretion but had no effect on regulated on activation, normal T cells expressed and secreted (RANTES) levels. More importantly, such calcium-mobilizing agents significantly enhanced TNF-alpha-induced IL-6 secretion while RANTES secretion was abrogated. The use of luciferase-tagged IL-6 and RANTES promoter constructs demonstrated similar effects of Tg on IL-6 and RANTES genes in basal and TNF-alpha-stimulated conditions. The cyclic adenosine monophosphate (cAMP)-dependent pathway plays a minor role in this differential regulation of IL-6 and RANTES genes expression. 2-Aminoethoxydiphenyl borate (APB), a blocker of store-operated calcium channels (SOCs), and bisindolylmaleimide I (Bis I), a broad-spectrum protein kinase C (PKC) inhibitor, inhibited the basal and synergic effects of IL-6 secretion in response to calcium-mobilizing agents and TNF-alpha, but did not prevent the abrogated effect of RANTES secretion. We also found that Go-6976, a selective calcium-dependent PKC isozyme inhibitor, did not inhibit IL-6 secretion in response to GPCR agonist and TNF-alpha; whereas Rottlerlin, a PKC-delta inhibitor, inhibited both Thr- and TNF-alpha-induced expression of IL-6, while BK-induced IL-6 secretion was not affected. Interestingly, TNF-alpha-induced interferon regulatory factor (IRF)-1 activation was significantly inhibited by all calcium-mobilizing agents, BK, Thr and Tg. These results show that calcium-mobilizing GPCR agonists functionally interact with TNF-alpha to differentially regulate pro-inflammatory genes expression in human ASM cells, possibly by involving Tg-sensitive intracellular calcium stores, SOC and PKC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228299     DOI: 10.1007/s11373-005-9008-z

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  4 in total

1.  TNF-α potentiates lysophosphatidic acid-induced COX-2 expression via PKD in human colonic myofibroblasts.

Authors:  Citlali Ekaterina Rodriguez Perez; Wenxian Nie; James Sinnett-Smith; Enrique Rozengurt; James Yoo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-03       Impact factor: 4.052

Review 2.  Regulation of G-protein-coupled signaling pathways in allergic inflammation.

Authors:  Kirk M Druey
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-β amplification loop.

Authors:  Jessie W Yester; Lauren Bryan; Michael R Waters; Bartosz Mierzenski; Debolina D Biswas; Angela S Gupta; Reetika Bhardwaj; Michael J Surace; Jose M Eltit; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  FASEB J       Date:  2015-08-05       Impact factor: 5.191

Review 4.  Ion channel regulation of intracellular calcium and airway smooth muscle function.

Authors:  Jose F Perez-Zoghbi; Charlotta Karner; Satoru Ito; Malcolm Shepherd; Yazan Alrashdan; Michael J Sanderson
Journal:  Pulm Pharmacol Ther       Date:  2008-10-19       Impact factor: 3.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.